New Study Finds Morning After Pill Can Work as an Abortion Drug 
Email this article
Printer friendly page
by Steven Ertelt
LifeNews.com Editor
May 28, 2007
Washington, DC (LifeNews.com) — A new study published in the medical journal Fertility and Sterility finds that the Plan B drug, known as the morning after pill, can work to cause an abortion of a human being after her life has started. Abortion advocates have claimed the drug only prevents conception but the study appears to contradict that claim.
Dr. Rafael T. Mikolajczyk of the School of Public Health at the University of Bielefeld in Germany and Dr. Joseph B. Stanford, who teaches public health at the University of Utah, are the senior authors of the paper.
Combining data from multiple studies, they found that levonorgestrel, the drug contained in "emergency contraception," works to prevent the implantation of the developing human being after fertilization occurs.
As a result of that process, the developing baby cannot implant into the mother’s uterus and complete the rest of the growth and development process that leads to birth. Ultimately, the study found that drug works to make the uterus inhospitable to life and the unborn child dies.
Ruben Obregon, the president of the No Room for Contraception Campaign, brought the study to the attention of LifeNews.com.
He pointed out that the study found that the Plan B pill was only 8%-49% effective depending on the amount of delay in using it after intercourse. When used immediately, it was 49 percent effective in preventing conception but that dropped to 8 percent if the user of the drug waits until 72 hours after intercourse.
When the abortifacient mechanism had an effect, the effectiveness ranged from 16% to 90% in preventing birth depending on whether there was any delay or a lag time as much as 72 hours.
The results of the study could have a significant impact on the debate surrounding the drug.
Abortion advocates have long claimed that the Plan B drug would reduce the number of abortions even though studies and actual data following its usage contradict those claims.
They were eventually successful in lobbying the FDA to approve over the counter sales of the drug to anyone over the age of 18.
The abstract can be found at:
https://www.fertstert.org/article/PIIS0015028206047327/abstract
